Explore

Rapid Read Rapid Read
ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen, the Clinical Genome Resource, and the Clinical Pharmacogenomics Resource (ClinPGx), which includes the Clinical Pharmacogenetics Implementation Consortium (CPIC), have formed a critical partnership. This collaboration aims to expand ClinGen’s extensive clinical genetics resources to incorporate pharmacogenomics (PGx) knowledge. ClinPGx serves as a primary resource for the PGx research and implementation communities, offering expert-curated gene-drug and variant-drug summaries based on peer-reviewed publications, clinical guidelines, and regulatory drug labels. The partnership facilitates the characterization and dissemination of the clinical relevance of pharmacogenetic variations through transparent and documented Standard Operating Procedures (SOPs). While ClinGen’s Expert Panels focus on gene-disease relationships, ClinPGx specializes in gene-drug and variant-drug associations, providing a comprehensive view of how genetic variations influence drug responses. This integration ensures that pharm...
Trendline Trendline
Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements
Trendline Trendline
Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost
Rapid Read Rapid Read
Prostate Cancer Screening Advances Improve Early Detection and Personalized Care

Prostate Cancer Screening Advances Improve Early Detection and Personalized Care

Advances in prostate cancer screening are improving early detection and offering more personalized care options for men in the United States. According to Mina Fam, M.D., medical director of urologic oncology at Hackensack Meridian Jersey Shore University Medical Center, while prostate cancer remains the second-leading cause of cancer death among American men, most men diagnosed do not die from it. The PSA (prostate-specific antigen) blood test has returned as a standard starting point for screening, aiming to establish a healthy baseline and identify potential issues early. Screening timelines are now highly individualized, with discussions beginning around age 50 for average-risk men, age 45 for Black men and those with a family history, and between ages 40 and 45 for men with a known genetic predisposition like a BRCA mutation. A significant development is that an elevated PSA no longer automatically leads to a biopsy; instead, advanced MRI tests and new blood and urine biomarkers are used to determine ...
Rapid Read Rapid Read
Mayo Clinic and Virginia Tech Identify Five Subgroups of Non-Alcoholic Fatty Liver Disease

Mayo Clinic and Virginia Tech Identify Five Subgroups of Non-Alcoholic Fatty Liver Disease

A collaborative study by the Mayo Clinic and Virginia Tech, published in Nature Communications, has identified five distinct subgroups of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease. Researchers analyzed clinical histories and genetic data from over 4,600 patients to uncover patterns that were previously obscured when MASLD was treated as a single condition. The study categorized these subgroups, labeled C1 through C5, each exhibiting different clinical characteristics and risks. For instance, C2 predominantly featured men with a cardiorenal profile, while C3 was more common in women and linked to obesity and mood disorders. Notably, C4, despite having fewer metabolic comorbidities, showed the highest rate of liver transplants, attributed to an unfavorable combination of genetic variants. C5, characterized as polygenic MASLD/MASH, presented a higher risk of advanced fibrosis and acute renal failure. This research suggests that MASLD ...
Rapid Read Rapid Read
Biomarker Science Advances Drive Shift Towards Predictive Preventive Medicine in Healthcare

Biomarker Science Advances Drive Shift Towards Predictive Preventive Medicine in Healthcare

Healthcare systems are increasingly focusing on predictive medicine, utilizing advances in imaging, molecular testing, and biomarker science to identify disease risks before symptoms manifest. This shift aims to move clinical and financial value upstream by predicting diseases rather than solely treating them after diagnosis. Chronic conditions currently account for the majority of health expenditures in advanced economies, with most spending occurring post-diagnosis. Preventive medicine, through early detection and screening, seeks to alter this dynamic by delaying disease onset and avoiding associated costs. The commercial market for screening is expanding, attracting private capital into tests, imaging, and monitoring services that were traditionally funded by public health budgets. Key thematic areas driving this evolution include population screening, cancer screening pathways, biomarker validation, advanced imaging with AI-assisted interpretation, at-home sample collection, and occupational health sc...
Rapid Read Rapid Read
International Study Suggests Type 1 Diabetes May Be Two Distinct Diseases

International Study Suggests Type 1 Diabetes May Be Two Distinct Diseases

A massive international study has found evidence suggesting that Type 1 diabetes may actually be two different diseases, rather than a single condition. The research, published in Diabetologia, focused on two genetic patterns, HLA-DR3 and HLA-DR4, which are associated with a higher risk of Type 1 diabetes. While both patterns lead to the same end result of Type 1 diabetes, the early signs and underlying biological mechanisms appear to differ significantly between them. Researchers from the U.S. and UK conducted the first-ever genome-wide association study (GWAS) that separated Type 1 diabetes patients based on these two genetic signatures. The study involved 9,091 individuals with Type 1 diabetes and 14,157 control subjects. The findings indicated enough genetic differences between the HLA-DR3 and HLA-DR4 groups to suggest distinct subtypes of the disease. Specifically, the HLA-DR3 results pointed towards the involvement of mast cells, which are linked to allergies and inflammation, while the HLA-DR4 genet...
Rapid Read Rapid Read
Mount Sinai Establishes Center for Genomic AI and Microbiome Medicine to Advance Precision Medicine

Mount Sinai Establishes Center for Genomic AI and Microbiome Medicine to Advance Precision Medicine

Mount Sinai has launched a new Center for Genomic AI and Microbiome Medicine. This center aims to advance precision medicine by integrating complex human genomic and microbiome data using genomic AI models. The research will focus on understanding biological mechanisms linked to disease progression and treatment response. Initially, the center will concentrate on neurodegenerative diseases, including Alzheimer's and Parkinson's, as well as gastrointestinal cancer. The center will leverage expertise in genomics, systems biology, microbiome science, computational modeling, data science, and clinical research. Researchers will utilize long-read sequencing to examine DNA, retain molecular context, differentiate microbial strains, and study genetic and epigenetic variations in greater detail. The goal is to identify how integrated genetic and microbiome profiles can support earlier risk assessment, clarify variations in drug response and toxicity, and inform future diagnostic and therapeutic strategies.
Rapid Read Rapid Read
AI-Driven Diagnostic Tools Advance Precision Sleep Medicine

AI-Driven Diagnostic Tools Advance Precision Sleep Medicine

Artificial intelligence (AI) is revolutionizing the diagnosis and understanding of sleep disorders, paving the way for precision sleep medicine. New AI-driven diagnostic tools are enabling more accurate and accessible detection and characterization of sleep disorders by automating the analysis of physiological signals such as EEG, oximetry, and cardiorespiratory data. These advancements allow for diagnoses from simpler recordings than traditional polysomnography, often in ambulatory and home settings. The focus is on developing, validating, and applying these tools to advance personalized, precision-based sleep care, ensuring they perform reliably across specific clinical or at-risk groups. This includes novel algorithms, robust validation studies, interpretability, and seamless integration into clinical workflows, moving from signal acquisition to diagnosis.
Rapid Read Rapid Read
WIN Consortium to Host 2026 Symposium on Personalized Cancer Medicine in Rhode Island

WIN Consortium to Host 2026 Symposium on Personalized Cancer Medicine in Rhode Island

The WIN Consortium is organizing a symposium on personalized cancer medicine, scheduled for October 2-3, 2026, at the Rhode Island Convention Center. This event aims to bring together experts and researchers to discuss advancements in precision oncology. A notable aspect of the symposium is the waiver of registration fees for college and precollege students who submit an abstract relevant to precision oncology research. This includes studies on tools and artificial intelligence (AI) designed to facilitate precision medicine globally. Accepted abstracts will be featured in the symposium's program, providing a platform for students to present their research, learn from professionals, network, and receive feedback. The initiative seeks to encourage participation from the next generation of scientists and foster innovation in the field of personalized cancer treatment.
Rapid Read Rapid Read
FDA Approves Novel Cellular Therapies and Expanded Indications for Solid Tumors, Advancing Precision Oncology

FDA Approves Novel Cellular Therapies and Expanded Indications for Solid Tumors, Advancing Precision Oncology

The U.S. Food and Drug Administration (FDA) has recently granted expanded indications and approved a novel cellular therapy for the treatment of solid tumors. This development significantly impacts oncology by enabling customized medicines based on individual patients' specific genetic mutations, bioprocesses, or immune system characteristics. Among the new approvals, Amtagvi (lifileucel) stands out as the first and only cellular therapy to receive FDA approval for a solid tumor cancer, specifically for unresectable advanced melanoma. Additionally, Enhertu (fam-trastuzumab deruxtecan, T-Dxd) received accelerated approval for adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and lack satisfactory alternative options. These approvals underscore a growing trend in precision medicine, where treatments are tailored to a patient's unique cancer characteristics, moving away from one-size-fits-all approaches. The pipeline for oncology drugs heavily...
Rapid Read Rapid Read
New Dried-Blood Method Accelerates Zika and Hepatitis C Diagnosis, Enhancing Global Accessibility

New Dried-Blood Method Accelerates Zika and Hepatitis C Diagnosis, Enhancing Global Accessibility

A new diagnostic method has been developed that enables the direct detection of hepatitis C and Zika virus from dried whole blood samples. This innovative approach bypasses the complex and equipment-intensive sample preparation steps typically required for conventional laboratory diagnostics, such as centrifugation, extraction, and purification. According to Rashid Bashir, PhD, professor of bioengineering at the University of Illinois Urbana-Champaign, the method captures and stabilizes target RNA molecules by drying the blood sample. RNA amplification can then be performed directly on the sample using dried primers and reagents, eliminating the need for cold-chain logistics. The entire diagnostic workflow only requires a simple heater for preparation and amplification, along with a compact, low-cost fluorescence reader for signal detection, maintaining accuracy comparable to standard-of-care methods while significantly improving accessibility and availability.